Regulatory PathRegulatory requirements compared

Active substance

Almotriptan

Open in the medicines table

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
ALMOTRIPTAN0242402912.5 MGTABLET · ORALPRO DOC LIMITEE
ALMOTRIPTAN0246682112.5 MGTABLET · ORALSANIS HEALTH INC
MYLAN-ALMOTRIPTAN023984356.25 MGTABLET · ORALMYLAN PHARMACEUTICALS ULC
MYLAN-ALMOTRIPTAN0239844312.5 MGTABLET · ORALMYLAN PHARMACEUTICALS ULC
SANDOZ ALMOTRIPTAN0240533412.5 MGTABLET · ORALSANDOZ CANADA INCORPORATED
TEVA-ALMOTRIPTAN0243484912.5 MGTABLET · ORALTEVA CANADA LIMITED

UK MHRA United Kingdom — marketing authorisations

ProductAuthorisationHolderLegal status
ALMOTRIPTAN GALENICUM 12.5 MG FILM-COATED TABLETSPL 00142/1241ACCORD-UK LIMITEDPOM

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffAlmotriptan 12.5mg tablets£3.263 tablet1 Oct 2026
NHS Drug TariffAlmotriptan 12.5mg tablets£6.526 tablet1 Oct 2026
NHS Drug TariffAlmotriptan 12.5mg tablets£9.789 tablet1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.